Ocata Therapeutics Inc fka OCAT

[rocky301]

Or is there something specific hurting the chances ?
The following needs to be done prior to any NIH approval. This has stalled out due to lawsuits etc;

(February 2010)
WASHINGTON - The National Institute of Health's proposal to revise its definition of human embryonic stem cells (hESC) to permit earlier stage embryos may at first glance appear to be a minor technical change. But to firms like Advanced Cell Technology Inc., which has sunk a "fortune" into developing the cell lines, it is "hugely important," said Robert Lanza, chief scientific officer for the Worcester, Mass.-based biotech.

The NIH late Friday afternoon proposed changing the definition of hESCs issued in guidelines last July from "cells that are derived from the inner cell mass of blastocyst stage human embryos" to "pluripotent cells that are derived from early stage human embryos, up to and including the blastocyst stage." (See BioWorld Today, July 7, 2009, and Feb. 22, 2010.)

That change would allow ACT's five single-blastomere lines currently under review at the NIH to receive federal funding for research, if approved by the agency. ACT currently has an investigational new drug application (IND) under review at the FDA for a Phase I/II trial using its MA09 single-blastomere line to treat Stargardt disease, a genetic condition and the leading cause of juvenile blindness in the U.S., Lanza told BioWorld Today.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46950661